In the past five years this pharma company has gone from reversing into an AIM-quoted shell to the brink of being one of the top 100 AIM companies by market capitalisation when its latest acquisition is approved by shareholders at the end of July.
There is still plenty of growth in revenues to come from the company’s two niche drugs, because they are still at an early stage of commercialisation and there are more markets where they can be launched. The latest purchase brings a third drug into the portfolio. There are more specialist treatments in development.
Management has already iden...
